We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Guidance Addresses Individual Case Safety Reports for Clinical Trials
EMA Guidance Addresses Individual Case Safety Reports for Clinical Trials
November 17, 2010
Reports of suspected unexpected serious adverse reactions (SUSARs) occurring in clinical trials in the European Economic Area will soon have to include an assessment of any drug or drugs suspected of playing a role in the event, according to final guidance by the European Medicines Agency (EMA).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor